Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (A
about
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study.Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?Pegylated liposomal doxorubicin in the management of ovarian cancerTolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic reviewSarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015).Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicinOvarian cancer: in search of better marker systems based on DNA repair defectsClinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancerPhase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-baseCarboplatin and Liposomal Doxorubicin for Ovarian Cancer.DOXIL when combined with Withaferin A (WFA) targets ALDH1 positive cancer stem cells in ovarian cancerSystemic therapy in recurrent ovarian cancer: current treatment options and new drugs.Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.What is the role of chemotherapy in endometrial cancer?Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts.Anthracycline-based chemotherapy in metastatic endometrial carcinoma: an update.The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.Pegylated liposomal doxorubicin in ovarian cancer.Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study.
P2860
Q33387755-AB00CB30-95F6-4761-A365-60CFCD2C4FD8Q33633962-79357ED9-1180-41FA-8788-A562BAEDBEBBQ34187661-D2F2D968-EAD4-4649-97B8-73F8963E6BCDQ35583734-8FFF95E2-AC86-4E73-B5B8-799EE75FEB43Q36295510-2EBB027D-7793-420F-A793-5EA59A795966Q36430920-C14BBCAE-2649-4FDC-ADFB-A77BD08B0028Q36589947-F9B9BAE3-3D3F-4960-BA17-E851B4CD934EQ36728989-FB61EE6C-D3ED-4F43-9600-C00131037079Q36947397-50EFC8BF-44E9-462E-B667-36CE985C193EQ37016053-A858F8A4-3B5E-473F-97A3-26D5EDB3A5B9Q37276254-E8E09BD9-B45F-4FF3-89A5-1C93B1AE5EEBQ37656225-556A788C-C6D4-4929-AB10-C532466FFA5BQ37765581-CBE01DAA-3ECD-4890-BFBA-6649A15EC02FQ37923341-E76A06B2-93D3-46EF-8846-8BBC5647A7D5Q37965631-04CCD8F6-5B65-45AC-9A8E-D2A339D834FDQ38061964-26E3CD59-E64E-4E5E-995C-C73F38437515Q39282981-CBDDE097-E5D4-477A-AF07-DEF9FD2FF395Q43065300-A94C24DB-1DD6-4180-8D60-BD2B61449D3AQ44616736-C5336377-4887-476C-A79E-3C4363295229
P2860
Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (A
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Combination therapy with pegyl ...... OVAR) and Kommission Uterus (A
@ast
Combination therapy with pegyl ...... OVAR) and Kommission Uterus (A
@en
type
label
Combination therapy with pegyl ...... OVAR) and Kommission Uterus (A
@ast
Combination therapy with pegyl ...... OVAR) and Kommission Uterus (A
@en
prefLabel
Combination therapy with pegyl ...... OVAR) and Kommission Uterus (A
@ast
Combination therapy with pegyl ...... OVAR) and Kommission Uterus (A
@en
P2093
P1433
P1476
Combination therapy with pegyl ...... OVAR) and Kommission Uterus (A
@en
P2093
Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom
C Jackisch
J Pfisterer
Kommission Uterus
N Burchardi
P304
P356
10.1016/J.YGYNO.2007.08.008
P407
P577
2007-10-25T00:00:00Z